Company webinar

Neurizon Therapeutics (ASX:NUZ)

Watch our webinar with Neurizon Therapeutics, featuring Interim Executive Chairman Sergio Duchini and CFO Dan O'Connell. A presentation followed by live Q&A with the audience.

Date
September 30, 2026
Time
Where
Online
Entry
Free
Sergio Duchini
Sergio Duchini
Interim Executive Chairman, Neurizon Therapeutics (ASX:NUZ)
Dan O'Connell
Dan O'Connell
CFO, Neurizon Therapeutics (ASX:NUZ)

About the company

Neurizon Therapeutics (ASX: NUZ; OTCQB: NUZTF) is a clinical-stage biotechnology company developing NUZ-001 for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease.

NUZ-001 is currently being evaluated in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial in the United States, which has completed recruitment of 250 participants and is progressing toward topline results anticipated in late Q2 CY2027. Neurizon has also recently established an NIH-funded Expanded Access Program through the Healey & AMG Center, broadening patient access to NUZ-001 and further strengthening the clinical infrastructure around the program.

Key topics

  • Neurizon and the NUZ-001 investment case
  • NIH-funded Expanded Access Program
  • HEALEY ALS Platform Trial and path to topline data
  • How Neurizon has de-risked the business over the past six months
  • The next 12 months and potential value inflection points

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →